nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2010

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

verfasst von: James P. Sullivan, John D. Minna, Jerry W. Shay

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The discovery of rare tumor cells with stem cell features first in leukemia and later in solid tumors has emerged as an important area in cancer research. It has been determined that these stem-like tumor cells, termed cancer stem cells, are the primary cellular component within a tumor that drives disease progression and metastasis. In addition to their stem-like ability to self-renew and differentiate, cancer stem cells are also enriched in cells resistant to conventional radiation therapy and to chemotherapy. The immediate implications of this new tumor growth paradigm not only require a re-evaluation of how tumors are initiated, but also on how tumors should be monitored and treated. However, despite the relatively rapid pace of cancer stem cell research in solid tumors such as breast, brain, and colon cancers, similar progress in lung cancer remains hampered in part due to an incomplete understanding of lung epithelial stem cell hierarchy and the complex heterogeneity of the disease. In this review, we provide a critical summary of what is known about the role of normal and malignant lung stem cells in tumor development, the progress in characterizing lung cancer stem cells and the potential for therapeutically targeting pathways of lung cancer stem cell self-renewal.

Reya, T., et al. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105–111.PubMed

Clarke, M. F., & Fuller, M. (2006). Stem cells and cancer: two faces of eve. Cell, 124(6), 1111–1115.PubMed

Wicha, M. S., Liu, S. L., & Dontu, G. (2006). Cancer stem cells: an old idea—a paradigm shift. Cancer Research, 66(4), 1883–1890.PubMed

Passegue, E., Wagner, E. F., & Weissman, I. L. (2004). JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell, 119(3), 431–443.PubMed

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.PubMed

Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.PubMed

Costello, R. T., et al. (2000). Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Research, 60(16), 4403–4411.PubMed

Wulf, G. G., et al. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood, 98(4), 1166–1173.PubMed

Misaghian, N., et al. (2009). Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 23(1), 25–42.PubMed

10.

Singh, S. K., et al. (2004). Identification of human brain tumour initiating cells. Nature, 432(7015), 396–401.PubMed

11.

Ponti, D., et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research, 65(13), 5506–5511.PubMed

12.

Patrawala, L., et al. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 25(12), 1696–1708.PubMed

13.

Ricci-Vitiani, L., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445(7123), 111–115.PubMed

14.

O'Brien, C. A., et al. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106–110.PubMed

15.

Li, C. W., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030–1037.PubMed

16.

Eramo, A., et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 15(3), 504–514.PubMed

17.

Minna, J. D., Roth, J. A., & Gazdar, A. F. (2002). Focus on lung cancer. Cancer Cell, 1(1), 49–52.PubMed

18.

Jemal, A., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4), 225–249.

19.

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007). Lung cancer in never smokers—a different disease. Nature Reviews Cancer, 7(10), 778–790.PubMed

20.

Knight, D. A., & Holgate, S. T. (2003). The airway epithelium: structural and functional properties in health and disease. Respirology, 8(4), 432–446.PubMed

21.

Mercer, B. A., et al. (2006). The epithelial cell in lung health and emphysema pathogenesis. Current Respiratory Medicine Revue, 2(2), 101–142.

22.

Bowden, D. H. (1983). Cell turnover in the lung. American Review of Respiratory Disease, 128(2 Pt 2), S46–S48.PubMed

23.

Kauffman, S. L. (1980). Cell proliferation in the mammalian lung. International Review of Experimental Pathology, 22, 131–191.PubMed

24.

Rawlins, E. L., & Hogan, B. L. (2008). Ciliated epithelial cell lifespan in the mouse trachea and lung. American Journal of Physiology. Lung Cellular and Molecular Physiology, 295(1), L231–L234.PubMed

25.

Giangreco, A., et al. (2009). Stem cells are dispensable for lung homeostasis but restore airways after injury. Proceedings of the National Academy of Sciences of the United States of America, 106(23), 9286–9291.PubMed

26.

Rawlins, E. L., & Hogan, B. L. (2006). Epithelial stem cells of the lung: privileged few or opportunities for many? Development, 133(13), 2455–2465.PubMed

27.

Evans, M. J., et al. (2001). Cellular and molecular characteristics of basal cells in airway epithelium. Experimental Lung Research, 27(5), 401–415.PubMed

28.

Boers, J. E., Ambergen, A. W., & Thunnissen, F. B. (1998). Number and proliferation of basal and parabasal cells in normal human airway epithelium. American Journal of Respiratory and Critical Care Medicine, 157(6 Pt 1), 2000–2006.PubMed

29.

Schoch, K. G., et al. (2004). A subset of mouse tracheal epithelial basal cells generates large colonies in vitro. American Journal of Physiology. Lung Cellular and Molecular Physiology, 286(4), L631–L642.PubMed

30.

Nakajima, M., et al. (1998). Immunohistochemical and ultrastructural studies of basal cells, Clara cells and bronchiolar cuboidal cells in normal human airways. Pathology International, 48(12), 944–953.PubMed

31.

Donnelly, G. M., Haack, D. G., & Heird, C. S. (1982). Tracheal epithelium: cell kinetics and differentiation in normal rat tissue. Cell and Tissue Kinetics, 15(2), 119–130.PubMed

32.

Breuer, R., et al. (1990). Cell kinetics of normal adult hamster bronchial epithelium in the steady state. American Journal of Respiratory Cell and Molecular Biology, 2(1), 51–58.PubMed

33.

Rawlins, E. L. (2008). Lung epithelial progenitor cells: lessons from development. Proceedings of the American Thorac Society, 5(6), 675–681.

34.

Hong, K. U., et al. (2004). In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations. American Journal of Physiology. Lung Cellular and Molecular Physiology, 286(4), L643–L649.PubMed

35.

Hong, K. U., et al. (2004). Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. American Journal of Pathology, 164(2), 577–588.PubMed

36.

Hajj, R., et al. (2007). Basal cells of the human adult airway surface epithelium retain transit-amplifying cell properties. Stem Cells, 25(1), 139–148.PubMed

37.

Randell, S. H., et al. (1991). Properties of rat tracheal epithelial cells separated based on expression of cell surface alpha-galactosyl end groups. American Journal of Respiratory Cell and Molecular Biology, 4(6), 544–554.PubMed

38.

Rock, J. R., et al. (2009). Basal cells as stem cells of the mouse trachea and human airway epithelium. Proceedings of the National Academy of Sciences of the United States of America, 106(31), 12771–12775.PubMed

39.

Barth, P. J., et al. (2000). Proliferation and number of Clara cell 10-kDa protein (CC10)-reactive epithelial cells and basal cells in normal, hyperplastic and metaplastic bronchial mucosa. Virchows Archiv, 437(6), 648–655.PubMed

40.

Boers, J. E., Ambergen, A. W., & Thunnissen, F. B. (1999). Number and proliferation of clara cells in normal human airway epithelium. American Journal of Respiratory and Critical Care Medicine, 159(5 Pt 1), 1585–1591.PubMed

41.

Buckpitt, A., et al. (1995). Relationship of cytochrome P450 activity to Clara cell cytotoxicity. IV. Metabolism of naphthalene and naphthalene oxide in microdissected airways from mice, rats, and hamsters. Molecular Pharmacology, 47(1), 74–81.PubMed

42.

Stripp, B. R., et al. (1995). Plasticity of airway cell proliferation and gene expression after acute naphthalene injury. American Journal of Physiology, 269(6 Pt 1), L791–L799.PubMed

43.

Stevens, T. P., et al. (1997). Cell proliferation contributes to PNEC hyperplasia after acute airway injury. American Journal of Physiology, 272(3 Pt 1), L486–L493.PubMed

44.

Reynolds, S. D., et al. (2000). Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. American Journal of Pathology, 156(1), 269–278.PubMed

45.

Reynolds, S. D., et al. (2000). Conditional clara cell ablation reveals a self-renewing progenitor function of pulmonary neuroendocrine cells. American Journal of Physiology. Lung Cellular and Molecular Physiology, 278(6), L1256–L1263.PubMed

46.

Hong, K. U., et al. (2001). Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. American Journal of Respiratory Cell and Molecular Biology, 24(6), 671–681.PubMed

47.

Simon, M., Argiris, A., & Murren, J. R. (2004). Progress in the therapy of small cell lung cancer. Critical Reviews in Oncology/hematology, 49(2), 119–133.PubMed

48.

Turrisi, A. T., & Sherman, C. A. (2002). The treatment of limited small cell lung cancer: a report of the progress made and future prospects. European Journal of Cancer, 38(2), 279–291.PubMed

49.

Watkins, D. N., et al. (2003). Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature, 422(6929), 313–317.PubMed

50.

Giangreco, A., Groot, K. R., & Janes, S. M. (2007). Lung cancer and lung stem cells - Strange bedfellows? American Journal of Respiratory and Critical Care Medicine, 175(6), 547–553.PubMed

51.

Adamson, I. Y., & Bowden, D. H. (1975). Derivation of type 1 epithelium from type 2 cells in the developing rat lung. Laboratory Investigation, 32(6), 736–745.PubMed

52.

Evans, M. J., et al. (1975). Transformation of alveolar type 2 cells to type 1 cells following exposure to NO2. Experimental and Molecular Pathology, 22(1), 142–150.PubMed

53.

Buckley, S., et al. (1998). Apoptosis and DNA damage in type 2 alveolar epithelial cells cultured from hyperoxic rats. American Journal of Physiology, 274(5 Pt 1), L714–L720.PubMed

54.

Reddy, R., et al. (2004). Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. American Journal of Physiology. Lung Cellular and Molecular Physiology, 286(4), L658–L667.PubMed

55.

Giangreco, A., Reynolds, S. D., & Stripp, B. R. (2002). Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. American Journal of Pathology, 161(1), 173–182.PubMed

56.

Kim, C. F., et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 121(6), 823–835.PubMed

57.

Jackson, E. L., et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 15(24), 3243–3248.PubMed

58.

Fisher, G. H., et al. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes and Development, 15(24), 3249–3262.PubMed

59.

Politi, K., et al. (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes and Development, 20(11), 1496–1510.PubMed

60.

Carney, D. N., Gazdar, A. F., & Minna, J. D. (1980). Positive correlation between histological tumor involvement and generation of tumor cell colonies in agarose in specimens taken directly from patients with small-cell carcinoma of the lung. Cancer Research, 40(6), 1820–1823.PubMed

61.

Carney, D. N., et al. (1982). Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells, 1(3), 149–164.PubMed

62.

Gazdar, A. F., et al. (1981). Heterotransplantation of small-cell carcinoma of the lung into nude mice: comparison of intracranial and subcutaneous routes. International Journal of Cancer, 28(6), 777–783.

63.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8(10), 755–768.PubMed

64.

Goodell, M. A., et al. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Journal of Experimental Medicine, 183(4), 1797–1806.PubMed

65.

Zhou, S., et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine, 7(9), 1028–1034.PubMed

66.

Hirschmann-Jax, C., et al. (2004). A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 101(39), 14228–14233.PubMed

67.

Kondo, T., Setoguchi, T., & Taga, T. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proceedings of the National Academy of Sciences of the United States of America, 101(3), 781–786.PubMed

68.

Patrawala, L., et al. (2005). Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Research, 65(14), 6207–6219.PubMed

69.

Feuring-Buske, M., & Hogge, D. E. (2001). Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood, 97(12), 3882–3889.PubMed

70.

Szotek, P. P., et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 103(30), 11154–11159.PubMed

71.

Ho, M. M., et al. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67(10), 4827–4833.PubMed

72.

Zhong, Y., et al. (2007). Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342. Biochemical and Biophysical Research Communications, 364(2), 338–343.PubMed

73.

Platet, N., et al. (2007). Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Letters, 581(7), 1435–1440.PubMed

74.

Montanaro, F., et al. (2004). Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Experimental Cell Research, 298(1), 144–154.PubMed

75.

Wu, C., & Alman, B. A. (2008). Side population cells in human cancers. Cancer Letters, 268(1), 1–9.PubMed

76.

Mizrak, D., Brittan, M., & Alison, M. R. (2008). CD133: molecule of the moment. Journal of Pathology, 214(1), 3–9.PubMed

77.

Yin, A. H., et al. (1997). AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood, 90(12), 5002–5012.PubMed

78.

Uchida, N., et al. (2000). Direct isolation of human central nervous system stem cells. Proceedings of the National Academy of Sciences of the United States of America, 97(26), 14720–14725.PubMed

79.

Ghods, A. J., et al. (2007). Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells, 25(7), 1645–1653.PubMed

80.

Lee, J., et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9(5), 391–403.PubMed

81.

Bertolini, G., et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America, 106(38), 16281–16286.PubMed

82.

Levina, V., et al. (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE, 3(8), e3077.PubMed

83.

Meng, X., et al. (2009). Both CD133+ and CD133− subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Science, 100(6), 1040–1046.PubMed

84.

Howard, B. M., & Boockvar, J. A. (2008). Stem cell marker CD133 expression predicts outcome in glioma patients. Neurosurgery, 62(6), N8.

85.

Salnikov, A. V., et al. (2009). CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. International Journal of Cancer, 126, 950–958.

86.

Tirino, V., et al. (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 36(3), 446–453.PubMed

87.

Wang, J., et al. (2008). CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer, 122(4), 761–768.

88.

Shmelkov, S. V., et al. (2008). CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation, 118(6), 2111–2120.PubMed

89.

Bidlingmaier, S., Zhu, X., & Liu, B. (2008). The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. Journal of Molecular Medicine, 86(9), 1025–1032.PubMed

90.

Moreb, J., et al. (1996). Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Therapy, 3(1), 24–30.PubMed

91.

Chute, J. P., et al. (2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 103(31), 11707–11712.PubMed

92.

Chute, J. P., et al. (2005). Modulation of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Blood, 106(11), 488a.

93.

Pearce, D. J., & Bonnet, D. (2007). The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. Experimental Hematology, 35(9), 1437–1446.PubMed

94.

Cheung, A. M., et al. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia, 21(7), 1423–1430.PubMed

95.

Pearce, D. J., et al. (2005). Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells, 23(6), 752–760.PubMed

96.

Bar, E. E., et al. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 25(10), 2524–2533.PubMed

97.

Ginestier, C., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1(5), 555–567.PubMed

98.

Huang, E. H., et al. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic Stem Cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 69, 3382–3389.PubMed

99.

Chen, Y. C., et al. (2009). Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochemical and Biophysical Research Communications, 385(3), 307–313.PubMed

100.

Patel, M., et al. (2008). ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer, 59(3), 340–349.PubMed

101.

Jiang, F., et al. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Molecular Cancer Research, 7(3), 330–338.PubMed

102.

Moreb, J. S., et al. (2008). ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Molecular Cancer, 7, 87.PubMed

103.

Moreb, J. S., et al. (2007). Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by aldefluor flow cytometry-based assay. Cytometry Part B-Clinical Cytometry, 72B(4), 281–289.

104.

Al-Hajj, M., & Clarke, M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene, 23(43), 7274–7282.PubMed

105.

Kirstetter, P., et al. (2006). Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nature Immunology, 7(10), 1048–1056.PubMed

106.

Reya, T., et al. (2003). A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 423(6938), 409–414.PubMed

107.

Stripp, B. R., & Reynolds, S. D. (2008). Maintenance and repair of the bronchiolar epithelium. Proceedings of the American Thoracic Society, 5(3), 328–333.PubMed

108.

Reynolds, S. D., et al. (2008). Conditional stabilization of beta-catenin expands the pool of lung stem cells. Stem Cells, 26(5), 1337–1346.PubMed

109.

Zemke, A. C., et al. (2009). beta-Catenin is not necessary for maintenance or repair of the bronchiolar epithelium. American Journal of Respiratory Cell and Molecular Biology, 41(5), 535–543.PubMed

110.

Lemjabbar-Alaoui, H., et al. (2006). Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS ONE, 1, e93.PubMed

111.

Uematsu, K., et al. (2003). Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Research, 63(15), 4547–4551.PubMed

112.

Uematsu, K., et al. (2003). Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene, 22(46), 7218–7221.PubMed

113.

You, L., et al. (2004). Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene, 23(36), 6170–6174.PubMed

114.

Shi, Y., et al. (2007). Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. International Journal of Cancer, 121(6), 1175–1181.

115.

You, L., et al. (2004). An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Research, 64(15), 5385–5389.PubMed

116.

Daniel, V. C., Peacock, C. D., & Watkins, D. N. (2006). Developmental signalling pathways in lung cancer. Respirology, 11(3), 234–240.PubMed

117.

Reya, T., & Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature, 434(7035), 843–850.PubMed

118.

Litingtung, Y., et al. (1998). Sonic hedgehog is essential to foregut development. Nature Genetics, 20(1), 58–61.PubMed

119.

Pepicelli, C. V., Lewis, P. M., & McMahon, A. P. (1998). Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Current Biology, 8(19), 1083–1086.PubMed

120.

Bellusci, S., et al. (1997). Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development, 124(1), 53–63.PubMed

121.

Taipale, J., & Beachy, P. A. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature, 411(6835), 349–354.PubMed

122.

Nilsson, M., et al. (2000). Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proceedings of the National Academy of Sciences of the United States of America, 97(7), 3438–3443.PubMed

123.

Goodrich, L. V., & Scott, M. P. (1998). Hedgehog and patched in neural development and disease. Neuron, 21(6), 1243–1257.PubMed

124.

Vestergaard, J., et al. (2006). Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer, 52(3), 281–290.PubMed

125.

Chi, S., et al. (2006). Activation of the hedgehog pathway in a subset of lung cancers. Cancer Letters, 244(1), 53–60.PubMed

126.

Zhao, C., et al. (2009). Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 458(7239), 776–779.PubMed

127.

Peacock, C. D., et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104(10), 4048–4053.PubMed

128.

Liu, S., et al. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Research, 66(12), 6063–6071.PubMed

129.

Tremblay, M. R., et al. (2009). Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy. Expert Opinion on Therapeutic Patents, 19(8), 1039–1056.PubMed

130.

Hyman, J. M., et al. (2009). Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proceedings of the National Academy of Sciences of the United States of America, 106(33), 14132–14137.PubMed

131.

Dlugosz, A. A., & Talpaz, M. (2009). Following the hedgehog to new cancer therapies. New England Journal of Medicine, 361(12), 1202–1205.PubMed

132.

Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999). Notch signaling: cell fate control and signal integration in development. Science, 284(5415), 770–776.PubMed

133.

Collins, B. J., Kleeberger, W., & Ball, D. W. (2004). Notch in lung development and lung cancer. Seminars in Cancer Biology, 14(5), 357–364.PubMed

134.

Ito, T., et al. (2000). Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development, 127(18), 3913–3921.PubMed

135.

Borges, M., et al. (1997). An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature, 386(6627), 852–855.PubMed

136.

Guseh, J. S., et al. (2009). Notch signaling promotes airway mucous metaplasia and inhibits alveolar development. Development, 136(10), 1751–1759.PubMed

137.

Tsao, P. N., et al. (2008). Gamma-secretase activation of notch signaling regulates the balance of proximal and distal fates in progenitor cells of the developing lung. Journal of Biological Chemistry, 283(43), 29532–29544.PubMed

138.

Dang, T. P., et al. (2003). Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene, 22(13), 1988–1997.PubMed

139.

Konishi, J., et al. (2007). Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Research, 67(17), 8051–8057.PubMed

140.

Haruki, N., et al. (2005). Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Research, 65(9), 3555–3561.PubMed

141.

Zheng, Q., et al. (2007). Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncology Reports, 17(4), 847–852.PubMed

142.

Fan, X., et al. (2006). Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Research, 66(15), 7445–7452.PubMed

143.

Hoey, T., et al. (2009). DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell, 5(2), 168–177.PubMed

144.

Jiang, T. Y., et al. (2009). Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Research, 69(3), 845–854.PubMed

145.

Hill, R. P. (2006). Identifying cancer stem cells in solid tumors: case not proven. Cancer Research, 66(4), 1891–1895. discussion 1890.PubMed

146.

Kern, S. E., & Shibata, D. (2007). The fuzzy math of solid tumor stem cells: a perspective. Cancer Research, 67(19), 8985–8988.PubMed

147.

Kelly, P. N., et al. (2007). Tumor growth need not be driven by rare cancer stem cells. Science, 317(5836), 337.PubMed

148.

Quintana, E., et al. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 593–598.PubMed

149.

Li, Z., et al. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15(6), 501–513.PubMed

150.

Heddleston, J. M., et al. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle, 8(20), 3274–3284.PubMed

151.

Li, L., & Neaves, W. B. (2006). Normal stem cells and cancer stem cells: the niche matters. Cancer Research, 66(9), 4553–4557.PubMed

152.

Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells: mirage or reality? Nature Medicine, 15(9), 1010–1012.PubMed

153.

Mani, S. A., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMed

Titel: Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy
verfasst von: James P. Sullivan
John D. Minna
Jerry W. Shay
Publikationsdatum: 01.03.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9216-5

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

Modeling prostate cancer: a perspective on transgenic mouse models

Lung cancer: From single-gene methylation to methylome profiling

Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

EGFR mutations and the terminal respiratory unit

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie